Windlas Biotech Limited has announced that its Board of Directors will convene on Thursday, February 5, 2026, to review and approve the company's third-quarter financial performance for fiscal year 2026. The meeting has been scheduled in compliance with regulatory requirements under SEBI listing obligations.

Board Meeting Agenda

The primary agenda for the board meeting includes consideration and approval of unaudited financial results for the reporting period. The company will present both standalone and consolidated financial statements covering the quarter and nine months ended December 31, 2025.

Trading Window Restrictions

Windlas Biotech has implemented trading window restrictions in accordance with SEBI insider trading regulations. The trading window closure became effective from January 1, 2026, as communicated through the company's letter dated December 29, 2025. This measure ensures compliance with the SEBI Prohibition of Insider Trading Regulations 2015.

The company has specified that the trading window will reopen after the expiry of 48 hours from the date of declaration of the financial results. This standard practice helps maintain market integrity and prevents any potential misuse of unpublished price-sensitive information.

Regulatory Compliance

The board meeting notice has been issued pursuant to Regulation 29 of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results will be considered.

The formal communication was addressed to both major stock exchanges where the company's shares are listed - BSE Limited and National Stock Exchange of India Limited. Company Secretary and Compliance Officer Ananta Narayan Panda signed the official notice on January 28, 2026.

Windlas Biotech , a prominent player in the Indian pharmaceutical industry, has reported a robust 19% year-on-year revenue growth for both Q2 FY26 and H1 FY26. The company's performance highlights its continued momentum in the market, driven by strong contributions across its business verticals.

Financial Highlights

• Revenue from operations stood at INR 222.00 crores for Q2 FY26 and INR 432.00 crores for H1 FY26, both representing a 19% year-on-year growth.
• Earnings per share (EPS) for H1 FY26 reached INR 16.91, reflecting a 21% year-on-year increase.
• EBITDA was reported at INR 29.00 crores for Q2 FY26 and INR 55.00 crores for H1 FY26.
• Gross margins improved by 68 basis points in Q2 FY26 and 70 basis points in H1 FY26 year-on-year.
• The company maintained a strong liquidity position of INR 237.00 crores.

Business Vertical Performance

ESOP 2025 Scheme

Windlas Biotech announced the implementation of an Employee Stock Option Plan (ESOP) 2025 scheme. Key details include:

• Non-cash expenditure impact of INR 12.00 million in Q2 FY26.
• Covers approximately 100 employees across various management levels.
• Exercise price set at INR 5.00 per share.

Operational Updates

• The injectable facility has gained further customer approvals, with commercial supplies ramping up across both CDMO and Trade Generics verticals.
• Plant-6 expansion remains on track for commissioning within FY26, focusing primarily on oral solid dosage forms.
• The company paid a dividend of INR 12.20 crores, equivalent to INR 5.80 per share, for FY25.

Management Commentary

Hitesh Windlass, Managing Director of Windlas Biotech, commented on the results: "We are pleased to report another strong quarter, delivering a revenue increase of 19% in both Q2 FY26 and H1 FY26. The growth was driven by steady and balanced contributions across our three business verticals, with quality standards remaining at the core of our strategy."

Komal Gupta, CEO and CFO, added: "Backed by strategic initiatives, disciplined execution, and a focus on sustainable value creation, the company recorded its 11th consecutive quarter of record revenue performance. We continue to strengthen our core capabilities and enhance efficiencies."

Windlas Biotech's consistent performance, coupled with its strategic initiatives in capacity expansion and employee retention, positions the company well for sustained growth in the competitive pharmaceutical market. The management's focus on quality, diversification across business verticals, and investment in human capital through the ESOP scheme demonstrates a comprehensive approach to long-term value creation for all stakeholders.